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Continuous glucose monitoring (CGM), while a relatively new technology, has the potential to transform care for
children with type 1 diabetes. Some, but not all studies, have shown that CGM can significantly improve
hemoglobin A1c levels and reduce time spent in the hypoglycemic range in children, particularly when used as
part of sensor-augmented pump (SAP) therapy. Despite the publication of recent clinical practice guidelines
suggesting CGM be offered to all children 8 years of age or older who are likely to benefit, and studies showing
that younger children can also benefit, this technology is not yet commonly used by children with type 1 diabetes.
Effects of CGM are enhanced when used on a near-daily basis (a use-dependent effect) and with insulin pump
therapy. Therefore, coordinated strategies are needed to help children and their families initiate and continue to
use this resource for diabetes care. This review introduces CGM to pediatric endocrinologists who are not yet
familiar with the finer details of this technology, summarizes current data showing the benefits and limitations of
CGM use in children, reviews specific case examples demonstrating when CGM can be helpful, and shows the
value of both retrospective and real-time CGM. It is hoped that this information leads to discussion of this
technology in pediatric endocrinology clinics as an important next step in improving the care of children with type
1 diabetes.
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Continuous glucose monitoring (CGM) has been shown
to be helpful in adults with diabetes and offers the po-
tential to improve care for children with type 1 diabetes
(T1D) beyond what can be achieved with self-moni-
toring of blood glucose (SMBG) alone. The Endocrine
Society now recommends CGM use starting at 8 years
of age for anyone with T1D able to use it on a near-daily
basis. Still, despite frequent use in large diabetes centers,
CGM is not commonly used for pediatric patients with
T1D [1,2]. One reason for this is a lack of infrastructure
and personnel qualified to teach patients, as access to a
multidisciplinary trained team needed to teach families
to use CGM effectively is generally not available to the
non-academic pediatric endocrinologist [2,3]. In addi-
tion, there is concern among providers about being over-
whelmed by the considerable amount of data obtained* Correspondence: jordan.pinsker@us.army.mil
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distribution, and reproduction in any medium[4], and about limited reimbursement for time spent
interpreting the data [5].
Previous reports show that fewer than 30% of children
with T1D have a hemoglobin A1c (HbA1c) less than 8%,
and children experience episodes of severe hypoglycemia
more frequently than adults [6]. Accordingly, there is in-
creasing interest among pediatric endocrinologists in
using CGM to improve HbA1c levels and reduce the in-
cidence of hypoglycemia in children. This corresponds
with patient/family interest in CGM as a means to pre-
vent hypoglycemia primarily, and improve diabetes con-
trol secondarily [7]. The full clinical potential impact of
CGM, however, is far from being realized since most
children with T1D do not use or have access to this
resource for their diabetes care [4]. A major barrier for
patients is that frequent use is required, with studies
showing that both adults and children only benefit
significantly if CGM is used more than 70% of the time
(≥ 5 days per week) [8]. In addition, there are important
limitations to CGM (such as inconsistency in both ac-
curacy and precision when measuring low blood sugars),entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ill-equipped to educate patients properly on these limita-
tions [9]. Identifying which children with T1D should
use CGM has proven difficult and requires teaching
families that CGM requires intensive management and
will not replace time-consuming SMBG.
This review introduces CGM to clinicians who are not
yet familiar with the details of the technology and sum-
marizes current data showing the benefits and limita-
tions of CGM use in children. Specific case examples are
provided that demonstrate when CGM can be helpful
and illustrate distinct qualities of both retrospective and
real-time (RT) CGM. It is hoped that this information
fosters discussion of use of this technology in pediatric
endocrinology clinics that have not been routinely using
this resource for the care of children with T1D.
The current state of CGM use in children with T1D
CGM is currently available in the United States (US) in
2 forms: Retrospective and RT. The only fully retrospec-
tive CGM system on the market in the US is the iPro 2
(Medtronic Diabetes). The iPro 2 measures interstitial
fluid (IF) glucose levels using a subcutaneous electrode
for up to 72 hours and does not require active calibra-
tion during its use. In Europe, an additional system, the
GlucoDay S (A. Menarini Diagnostics), is also approved.
Both systems are referred to as “professional CGM”
meaning that devices are owned by the clinic and are
inserted at a clinic appointment. Data obtained by CGM
is this setting is blinded and only available to view after
the device and the patient’s blood glucose meter are
downloaded in the clinic. The graphs and summary data
generated can help patients and diabetes team members
adjust their therapy. Small trials in children have shown
these retrospective devices to be helpful in identifying
post-prandial hyperglycemia and asymptomatic overnight
hypoglycemia [10-12].
In contrast, RT-CGM is designed for personal daily
use at home, enabling patients to view their glucose
levels every few minutes either on their insulin pump or
on a separate receiver. Once attached by the patient at
home, the device requires a short setup period followed
typically by 2 or more calibrations per day. Salient features
of current, commercially available stand-alone CGM sys-
tems are summarized in Figure 1.
All RT-CGM systems approved for use in the US
(Figures 1 and 2) allow patients to download data at
home for review and to either bring printouts to the
clinic or submit data via the internet using bundled soft-
ware packages, such as the CareLink or Diasend systems.
The latest versions of all of these systems support trend
graphs (viewing of glucose data in blocks of time),
threshold alarms for high and low blood glucose levels,
and rate of change alerts to show the direction and rateof glucose change. Some, such as the Medtronic and Ab-
bott systems, also support glucose prediction alerts. Be-
cause all of these devices measure IF, changes in sensor
readings typically lag 10 to 15 minutes behind changes
in blood glucose.
Differences in blood sugar readings from the CGM
and blood glucose meters, and the “false alarms” that re-
sult, can be frustrating to patients and their families
[13]. The mean absolute relative difference (MARD) be-
tween sensor readings and reference glucose levels can
vary by as much as 20%; such variations are especially
troubling in the hypoglycemic range [14-16]. The latest
generation of sensors from Medtronic (Enlite sensor – not
yet FDA approved in the US) and DexCom (G4 sensor)
report shorter lag times and further improvement in ac-
curacy, especially in the hypoglycemic range [17,18]. It is
important to emphasize to families that despite improve-
ments in sensor accuracy, FDA approval for CGM devices
in the US includes the recommendation that all treatment
decisions (i.e., treating suspected low or high blood glu-
cose) be based on fingerstick blood glucose, not sensor
readings.
CGM devices can be used with an insulin pump as
part of sensor-augmented pump (SAP) therapy or with
multiple daily injections. Some systems are fully inte-
grated into an insulin pump and use the pump display
to show CGM readings (Figure 2). The Medtronic Para-
digm Veo is currently the only system that includes a
low glucose suspend feature that can be set to halt in-
sulin delivery when glucose levels decline to a preset
hypoglycemic threshold as determined by CGM. The
sensors are approved to last only 3, 6, or 7 days, depend-
ing on the manufacturer. Thus far, off-label pediatric use
of all of these systems is common.
How can CGM help pediatric patients with T1D?
The following examples show typical blood sugar pattern
problems in children with T1D, often missed by SMBG,
that became apparent with CGM.
Case 1 – detection and treatment of hyperglycemia
Figure 3 shows the CGM summary graph of an 11-year-old
female with T1D who had just started on SAP therapy. Her
HbA1c was 7.4%. She was not aware of any particular
problems in her blood sugar control, and download of her
blood glucose meter showed most glucose readings were in
her target range. Review of the CGM data summary for the
few days prior to her appointment demonstrated
stable overnight glucose levels (Figure 3, Summary
Graph and Panel A), but examination of the CGM trend
graphs revealed a pattern of post-prandial hyperglycemia
(Figure 3, Panels B, C, and D). The data from CGM
provided an opportunity for further improvement of
glycemic control in this motivated, adherent patient and







Navigator 1.5 GlucoDay S 
Method Retrospective Real-Time Real-Time Real-Time Retrospective, but can be 
enabled for Real-Time 
FDA Approval All ages Age 7+ Adults  Adults *** Not approved 
European Approval All ages All Ages Adults Age 6+ All ages 
Sensor Duration 
3 days in US 
6 days in 
Europe/Canada/Israel* 
3 days in US 
6 days in 
Europe/Canada/Israel* 
7 days 5 days 2 days 
Frequency of 
Glucose Readings 
Every 5 min Every 5 min Every 5 min Every 1 min Every 3 min 




1 hour 2 hours 2 hours 1 hour None 
Feature Highlights No real-time  
calibration needed. 




transmitter. 7 day  
G4 sensor is 
waterproof.** 





* All current Medtronic CGM products are compatible with their updated Enlite sensor (currently under FDA review but 
approved in Europe, Canada and Israel) that is 69% smaller than their previous sensor and can be used for 6 days.
** The Dexcom G4 Platinum sensor/transmitter is waterproof at 2.4 meters for 24 hours.
*** Distribution of the Abbott FreeStyle Navigator was discontinued in the US in August 2011, but is still available in many 
European countries and Israel. 
Figure 1 Features of currently available stand-alone CGM systems (as of March 2013).
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post-prandial glucose levels with specific foods and timing
of bolus insulin doses.
Can CGM use consistently improve HbA1c in chil-
dren, particularly in patients, such as the one presented
above, who already demonstrate good glycemic control?
Meta-analyses of studies concluded prior to 2008 sho-
wed that CGM use was not superior to SMBG with re-
gard to metabolic control among pediatric patients with
T1D [19,20]. Similar results were reported from the
2008 landmark Juvenile Diabetes Research Foundation
CGM randomized controlled trial, in which overall blood
glucose control in children ages 8–17 years old assigned
to the CGM group did not differ from the SMBG group.
However, a subsequent sub-group analysis revealed that,
for the 21% of children who used CGM 6+ days a week,HbA1c levels were lowered by 0.8% without an increase in
hypoglycemia [21]. Subsequently, two multicenter, ran-
domized controlled trials of adults and children with good
control (HbA1c < 7.0% and 7.5%, respectively) demons-
trated that RT-CGM use was associated with a mean im-
provement of −0.3% in HbA1c, suggesting CGM use
could benefit patients whose HbA1c levels were already
near their target range [22,23]. Other recent studies also
support the effectiveness of frequent use of CGM in low-
ering HbA1c levels in children with T1D, and suggest SAP
therapy may offer the most benefit to children [24-28].
Case 2 – detection and correction of unrecognized
hypoglycemia
Figure 4 shows a retrospective CGM summary graph
from a 14-year-old female with T1D of 2 years duration,
Manufacturer setebaiDcinortdeMsaminAsetebaiDcinortdeM
Devices 




Sensor Duration 3 days in US 
6 days in Europe/Canada/Israel* 
7 days 
3 days in US 
6 days in Europe/Canada/Israel* 
Frequency of  
Glucose Readings nim5yrevEnim5yrevEnim5yrevE
Warm Up Period Before 
Glucose Readings are 
Displayed 
sruoh2sruoh2sruoh2
Feature Highlights Has predictive alerts. 
Pump and integrated Dexcom G4 
Platinum sensor are waterproof.** 
Color display. 
Has predictive alerts.  
Also has low glucose suspend 
option. 
The latest products integrate the CGM display graphs and alerts into the insulin pump screen. The Medtronic Paradigm Veo also
features a low glucose suspend feature that can automatically halt insulin delivery when the CGM sensor detects hypoglycemia.
* All current Medtronic CGM products are compatible with their updated Enlite sensor (currently under FDA review but 
approved in Europe, Canada and Israel) that is 69% smaller than their previous sensor and can be used for 6 days. 
** The Animus Vibe insulin pump is waterproof up to 3.6 meters for 24 hours. The Dexcom G4 Platinum sensor/transmitter is 
waterproof at 2.4 meters for 24 hours.
Figure 2 Features of currently available integrated CGM systems (as of March 2013).
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insulin via insulin pump. She came to the clinic 3 days
prior to her normal appointment and was set up with
the clinic’s retrospective CGM. At the appointment her
HbA1c level was found to be 7.9%, and her SMBG rec-
ord revealed scattered high and low blood sugars with
no consistent pattern. The patient and her family were
reluctant to alter insulin doses due to a history of prior
hypoglycemic seizures, and felt her current degree of
blood glucose control was satisfactory. However the
CGM summary graph of the previous 3 days showed
asymptomatic and undetected overnight low blood sugar
levels in the 60–80 mg/dL range and low blood sugarlevels beginning 1–2 hours after exercise in the evening
(Figure 4). Using these data from CGM, overnight basal
rate on her insulin pump was decreased slightly and the
patient was educated on use of the temporary basal fea-
ture (decreasing the basal rate on her insulin pump by
25% for the next 6 hours after exercise) to prevent hy-
poglycemia in the evening following exercise.
Fear of hypoglycemia limits many children from
attaining desired HbA1c goals [29]. For many children
with T1D, bedtime blood glucose checks are poor pre-
dictors of nocturnal hypoglycemia [10,11,30]. As noted
in the 2012 consensus guideline for pediatric CGM,
intermittent use of CGM (as demonstrated by the case
Figure 3 CGM summary graph for case 1. The entire 24-hour day appears at the top, with the dashed line showing the average reading.
Specific time periods are summarized in “trend graphs.” Overnight (Panel A) shows an average glucose reading of 130–140 mg/dL. After breakfast
(Panel B) shows post-prandial hyperglycemia averaging 250 mg/dL at 1 hour after the meal. Similar post-prandial hyperglycemia is shown after
lunch (Panel C) and after dinner (Panel D).
Figure 4 CGM summary graph for case 2. Asymptomatic hypoglycemia was identified overnight (Thursday and Friday night from 11 PM to
8 AM). Delayed hypoglycemia after early evening exercise was also observed, where glucose levels would rapidly drop later on between 9 and
10 PM (Wednesday and Thursday evening, arrows).
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prandial hyperglycemia, asymptomatic daytime and un-
recognized nocturnal hypoglycemia, and can aid in
evaluating the effects of changes in treatment regi-
mens [2]. However, initial studies of RT-CGM suggested
that its use did not reduce rates of hypoglycemia [31]. The
STAR1 trial of children using SAP therapy identified
“failure to respond to high and low alarms, and/or appro-
priately dose and administer insulin,” as the main con-
tributor to significantly higher rates of hypoglycemia [32].
The conclusion, therefore, is not that RT-CGM cannot
reduce hypoglycemia in patients using insulin pumps,
but rather that it needs to be used properly. More recent-
ly, multicenter, randomized controlled trials (discussed
above, showing that RT-CGM use lowered HbA1c levels
in adults and children with good baseline blood sugar
control), demonstrated that CGM use was associated with
reduced rates of hypoglycemia in both adults and children
[22,23]. Further, in the last year, two industry-sponsored
trials have shown significant improvements in HbA1c
levels in children while also reducing time spent with
blood sugar levels in the hypoglycemia range. The STAR3
trial of children using CGM showed a reduction in bloodFigure 5 CGM summary graph for case 3. This 18-year-old male used RT
13 hours of intense physical activity. Although he was hyperglycemic at th
drop rapidly (arrow). He consumed up to 75 grams of carbohydrates per h
the running event of the race.sugar level variability, favoring SAP use [25]. In addition,
the SWITCH Study Group’s trial of children and adults
showed that, in patients using SAP therapy, HbA1c levels,
as well as time spent with blood sugar levels in the hy-
poglycemia range, were reduced. [28].
Greater reductions in frequency and severity of hypo-
glycemia are likely with further integration of CGM into
the insulin pump, as now seen with the Medtronic Para-
digm Veo. Retrospective analyses of children and adults
using the “low glucose suspend” feature of the Paradigm
Veo, which automatically suspends insulin delivery for
up to 2 hours after a hypoglycemic event occurs as de-
termined by CGM, have shown both significant reduc-
tions in exposure to hypoglycemia and prevention of
profound rebound hyperglycemia after the CGM system
had automatically suspended insulin delivery for up to
2 hours [33,34].
Case 3 – glycemic variability with exercise
The RT-CGM graph from an 18-year-old male with
T1D recorded during an Ironman Triathlon is shown in
Figure 5. During his training period he wore his CGM
routinely, and developed a regimen of reduced basal-CGM while training for and competing in an Ironman Triathlon,
e start of the biking event, CGM showed his blood sugar began to
our while biking to avoid symptomatic hypoglycemia later on during
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for each of the running, cycling and swimming portions
of the event. The figure demonstrates how real-time
awareness of a decline in sensor blood glucose levels en-
abled him to avoid symptomatic hypoglycemia by con-
suming carbohydrates at a specific rate during a part of
this multi-hour competition.
CGM is a potentially powerful tool for athletes with
T1D. In one study of long distance runners, CGM iden-
tified frequent hypo- and hyperglycemic episodes during
and after races [35]. CGM can be applied to any of the
multiple strategies used to adjust insulin for strenuous
exercise, helping to customize an exercise plan for each
individual patient. For example, responding to CGM
“rate-of-change in blood sugar level alerts” by inges-
ting extra carbohydrates per a preset algorithm has been
shown to help adolescents prevent exercise induced hypo-
glycemia [36]. Similarly, the low glucose suspend feature
(described above) of the Medtronic Paradigm Veo has
been shown to significantly reduce the duration and sever-
ity of exercise-induced hypoglycemia in adults, without
causing significant rebound hyperglycemia [37].
Discussion
Continuous glucose monitoring has many theoretical
and, as described above, some demonstrated virtues.
However, many clinics that care for children with T1D
do not have clinical or financial support to facilitate
CGM use for all patients. Even today, it is not possible
or practical for many clinics to routinely download stan-
dard diabetes devices, despite the clear advantages down-
loading offers for observation of patterns not generallyFigure 6 Printout from a downloaded diabetes device. Note that, while
overwhelming amount of data displayed by this graph and similar printoutseen with written log books [3]. Clinicians who are not
practicing in large diabetes centers and not exposed to
CGM may feel intimidated by the technology, lack suffi-
cient time to coordinate with different online systems or
download new devices in clinic, and struggle to interpret
computer printouts due to format of the data displayed
(Figure 6). As suggested above, the abundance of data
generated and displayed can be confusing, preventing pa-
tients and clinicians from using the data well to make
timely and informed decisions [4]. To avoid such prob-
lems, clinics using CGM should have a program that al-
lows patients to: 1) download devices at home and print
out specifically desired summary graphs, pie charts, etc. or
2) download devices upon arrival in clinic, with a Certified
Diabetes Technologist Clinician assigned to obtain and
prepare the relevant data, or 3) download devices online
[38,39].
As with any technological aid for diabetes, the ma-
jor issue with CGM is encouraging consistent use [40].
While early acceptance of CGM is predictive of ex-
tended use, [41] children in particular show waning
adherence over time. It is important for families to
understand at the outset of CGM use that this technol-
ogy will not reduce the need to invest effort in diabetes
management. In fact, use of RT-CGM is often more time
consuming for patients because it forces them to con-
stantly focus on diabetes care [13,42]. Consequently, it is
important to offer achievable plans with realistic expec-
tations for patients so they can experience some suc-
cesses with the technology from the start. Targeting of
CGM to patients and families can also be enhanced by
offering in-clinic use of retrospective CGM to allowthis 24-hour glucose overlay includes useful information, the
s may discourage physicians from analyzing them.
Table 1 Common problems seen when starting CGM in
children and adolescents, and potential solutions
Problem Potential solution
• Painful sensor insertions. • Apply a lidocaine-based cream
45 to 60 minutes prior to insertion.
• Apply a cool pack prior to insertion
(may increase the risk of bleeding
at the insertion site).
• Sensors do not adhere to
the skin or cause irritation.
• Different tapes and wraps may
need to be used.
• Tegaderm, or a moleskin
tape (Duoderm), can be
placed under the sensor
and transmitter to act
as a barrier.
• Too many “nuisance alarms”
that do not agree with SMBG.
• Explain the concept of “lag time”
upfront.
• Limit calibration to times when
blood glucose levels are not
changing rapidly.
• Lower alarm threshold to
70 mg/dL, and use only the
low glucose alarm when first
starting CGM.
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Those who find it helpful can then be offered RT-CGM
for personal use.
It is also important for clinics themselves to have real-
istic objectives regarding CGM implementation. Larger
centers with “diabetes technology clinics” typically start
only a few children per month on CGM due to the time
and resources needed for training [13]. Some clinics
offer classes that introduce the concept of CGM, provide
hands-on exposure to the equipment, and then pres-
cribe CGM for patients and families expressing inte-
rest and motivation. Use of standard reference materials
(e.g. “Understanding Insulin Pumps and Continuous Glu-
cose Monitors” [43]) is recommended as a curriculum to
teach families to advance from insulin pump to SAP ther-
apy. Instruction of families in the use of evidence-based al-
gorithms to adjust their insulin regimen can also be
extremely helpful. One model is to use the rate of change
of glucose levels to alter the pre-meal bolus, with a change
of 1–2 mg/dL/min indicating the need for a 10% adj-
ustment in bolus dosing (up or down), and adjusting
the bolus dose by 20% when the CGM system alerts that
glucose levels are changing by more than 2 mg/dL/min
[3,44]. (In smaller children who exhibit greater insulin
sensitivity, these percentages may need downward adjust-
ment to 5% and 10%, respectively). With this strategy, pa-
tients immediately see that CGM enables use of dynamic
data to adjust their plan of care beyond what was previ-
ously offered by SMBG.
The cost of CGM remains a significant obstacle. It has
been estimated that CGM sensors cost over $4,000 per
person year in the US [31]. Although some insurance
companies now provide reimbursement for these de-
vices, particularly in patients with frequent hypoglyce-
mia, coverage for CGM overall remains inconsistent. In
addition, payment to providers for initiating CGM and
interpreting data remains challenging. Clinicians can claim
reimbursement in the US for the initiation of CGM and
interpretation of CGM data using Current Procedural
Terminology codes 95250 and 95251, although there are
strict limitations on the use of these procedure codes
amongst different insurers [45]. Other countries have dif-
ferent fee structures, with some European countries now
routinely covering retrospective CGM up to 4 times per
year [5,46].
Many additional challenges remain before CGM can
be offered routinely to all children. While patient and
family motivation predicts continued use [32], even the
most motivated families often report using CGM only
intermittently, despite recommendations for continuous
wear, due to inability to tolerate the large size of the
sensors and transmitters. Proper orientation regarding
differences between devices and the advantages and dis-
advantages of each system is therefore very important(Figures 1 and 2). Even after all of the data has been
presented, there are occasions where CGM identifies er-
ratic glycemic control without an obvious pattern. When
this occurs in patients who are already compliant with
their care plan, it may not be clear as to what interven-
tion will fix the underlying problem. These issues can
potentially discourage clinics from supporting CGM in
any form. Other challenges include finding the right
combination of adhesive and skin site preparation with
sensors sometimes falling off early or causing excessive
skin irritation [13,47], and “nuisance alarms” that inter-
fere with daily activities. These alarms may go off in the
middle of the night for low or high blood sugars and
may not correlate with blood glucose meter readings or
be set at appropriate thresholds [42]. Because there can
be a very large error rate for modern CGM systems at
extreme but clinically relevant glucose concentrations,
particularly for glucose values < 70 mg/dL when the glu-
cose is changing rapidly [9], patients and families must
be made aware of the limitations of the device they
are using.
Frequent problems encountered by children and ado-
lescents using CGM and possible solutions to these
problems are listed in Table 1. These problems likely
contribute to decreased use of CGM and negative re-
sults reported in some trials of younger children [48].
To address these barriers, details on site insertion, taping
techniques, and strategies for starting CGM have been
published by groups with clinical experience in this field,
and should be read and understood by clinic support staff
[13]. Using these techniques, many smaller children can
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dren already on insulin pump therapy, SAP therapy has
been shown to be effective [27].
Conclusions
CGM has the potential to transform care for children
with T1D, particularly when used as part of SAP the-
rapy. Consensus guidelines now exist to help physicians
choose the appropriate pediatric patient for CGM use
[2]. These guidelines encourage discussion with patients
to provide realistic expectations, understand limitations,
and target use of specific features of CGM that allow for
maximizing patient benefit. Recent advances such as the
low glucose suspend feature of the Medtronic Paradigm
Veo show that the first step in “closing the loop,” with
CGM sensors directing insulin delivery from the insulin
pump, has already begun. Advancement in CGM-linked
smart telemedicine systems [4,49], computerized analysis
of CGM data [50], and smaller insertion needles and de-
vices should ultimately allow pediatric endocrinologists
to offer routine use of CGM to all children with T1D.
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